Summary & Overview
HCPCS J1631: Haloperidol Decanoate Injection, per 50 mg
HCPCS Level II code J1631 denotes the injection of haloperidol decanoate billed per 50 mg unit. As a long‑acting injectable antipsychotic, this medication is important in the management of chronic psychotic disorders and has implications for medication adherence, outpatient behavioral health workflows, and pharmacy‑administration coordination nationwide. Payers commonly encountering this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
This publication provides national benchmarks and practical policy context for HCPCS Level II code J1631. Readers will find an overview of typical sites of service and service type, payer coverage patterns, and common billing modifiers associated with injectable medications. The report summarizes payment range considerations, claims processing factors relevant to long‑acting injectable antipsychotics, and coding scenarios that affect reimbursement and clinical administration workflows. It also outlines clinical context for use of haloperidol decanoate and implications for outpatient behavioral health providers and pharmacies.
The content is tailored for billing professionals, revenue cycle staff, behavioral health clinicians, and policy analysts seeking a concise reference on billing practices and payer interactions for J1631. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1631 represents an injection of haloperidol decanoate, with the billing unit defined as per 50 mg. This medication is a long-acting injectable antipsychotic formulation of haloperidol used for the treatment of schizophrenia and related psychotic disorders when a depot (long-acting) antipsychotic formulation is clinically indicated.
-
Service type: Medication administration (long-acting injectable antipsychotic)
-
Typical site of service: Outpatient clinic, psychiatric clinic, behavioral health center, or other ambulatory settings where intramuscular injections are administered
Clinical & Coding Specifications
Clinical Context
A typical patient is a 35–65-year-old adult with chronic schizophrenia or schizoaffective disorder who receives long-acting injectable antipsychotic therapy to improve adherence and reduce relapse. The medication is J1631 (haloperidol decanoate), billed per 50 mg vial. The usual workflow: outpatient behavioral health clinic or psychiatric clinic schedules the intramuscular deep gluteal injection every 4 weeks (or per prescriber plan) after a clinical assessment. A nurse verifies the medication order and dose, reviews allergies and recent adverse effects, obtains informed consent for the injection, prepares the syringe using aseptic technique, and administers the intramuscular injection. Post-injection monitoring for 15–30 minutes is performed to observe for acute extrapyramidal symptoms, sedation, or injection-site reactions. Documentation includes medication lot number, units administered, injection site, patient tolerance, and next scheduled dose. Typical sites of service are outpatient behavioral health clinic, psychiatric clinic, community mental health center, or ambulatory infusion center when long-acting antipsychotic injections are administered.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / default | When no special circumstance modifier applies; many payers accept claims without an appended modifier. |